
Truist Securities downgrades medical equipment maker Penumbra PEN.N to "hold" from "buy"
Boston Scientific BSX.N said on Thursday that it will buy PEN in a deal valued at about $14.5 billion
We don't see any major hurdles to this deal closing and believe it will be hard to top BSX given the smooth strategic fit, brokerage says
11 of 19 brokerages rate the stock "buy" and 8 "hold"; their median PT is $370
Including session's move, PEN up 34% in the last 12 months